Changes in Biomarkers of Exposure on Switching from a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects

Nicotine and Tobacco Research

Volumn 21, Issue 9, 2019, Pages 1220-1227

  Gale, Nathan ^a   McEwan, Mike ^a   Eldridge, Alison C ^a   Fearon, Ian M ^b   Sherwood, Neil ^c   Bowen, Edward ^d   McDermott, Simon ^e   Holmes, Emma ^e   Hedge, Andrew ^e   Hossack, Stuart ^e   Wakenshaw, Louise ^d   Glew, James ^e   Camacho, Oscar M ^a   Errington, Graham ^a   McAughey, John ^a   Murphy, James ^a   Liu, Chuan ^a   Proctor, Christopher J ^a  

^a BRITISH AMERICAN TOBACCO   (United Kingdom)

^b CELERION   (United States)

^c Neil Sherwood Consulting   (Switzerland)

^d 206 Carnegie Center   (United Kingdom)

^e Early Clinical Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NICOTINE;

ADULT; ADVERSE EVENT; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED STUDY; ELECTRONIC CIGARETTE; EPIDEMIOLOGY; FEMALE; HEATING; HUMAN; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO; URINE;

ADULT; BIOMARKERS; CIGARETTE SMOKING; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HEATING; HUMANS; JAPAN; MALE; MIDDLE AGED; NICOTINE; SMOKING CESSATION; TOBACCO PRODUCTS;

EID: 85071542339     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nty104     Document Type: Article

References (30)

1. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observations on male British doctors. BMJ. 1994;309(6959):901-911.
2. Institute of Medicine. Clearing the Smoke Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: The National Academies Press; 2001.
3. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, Vol. 11, Reversal of Risk After Quitting Smoking. Lyon, France: IARC; 2007.
4. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: The science base for tobacco harm reduction executive summary. Tob Control. 2001;10(2):189-195.
5. World Health Organization. WHO Report on the Global Tobacco Epidemic: Warning About the Dangers of Tobacco. Geneva, Switzerland: WHO; 2011.
6. Royal College of Physicians. Nicotine Without Smoke. Tobacco Harm Reduction. A Report by the Tobacco Advisory Group of the Royal College of Physicians. London, UK: RCP; 2016.
7. Perfetti T, Rodgman A. The complexity of tobacco and tobacco smoke. Beitr Tabakforsch. 2011;24(5):215-232.
8. Rees VW, Wayne GF, Thomas BF, Connolly GN. Physical design analysis and mainstream smoke constituent yields of the new potential reduced exposure product, Marlboro UltraSmooth. Nicotine Tob Res. 2007;9(11):1197-1206.
9. Dittrich DJ, Fieblekorn RT, Bevan MJ, et al. Approaches for the design of reduced toxicant emission cigarettes. Springerplus. 2014;3(1):374.
10. Shepperd CJ, Newland N, Eldridge A, et al. Changes in levels of biomarkers of exposure and biological effect in a controlled study of smokers switched from conventional cigarettes to reduced-Toxicant-prototype cigarettes. Regul Toxicol Pharmacol. 2015;72(2):273-291.
11. Smith MR, Clark B, Ludicke F, et al. Evaluation of the tobacco heating system 2.2. Part 1: description of the system and the scientific assessment program. Regul Toxicol Pharmacol. 2016;81(suppl 2): S17-S26.
12. Eaton D, Jakaj B, Forster M, et al. Assessment of tobacco heating product THP1.0. Part 2: product design, operation and thermophysical characterisation. Regul Toxicol Pharmacol. 2017;93(1):4-13.
13. Proctor C. Assessment of tobacco heating product THP1.0. Part 1: series introduction. Regul Toxicol Pharmacol. 2017;93(1):1-3.
14. Murphy J, Liu C, McAdam K, et al. Assessment of tobacco heating product THP1.0. Part 9: The placement of a range of next-generation products on an emissions continuum relative to cigarettes via preclinical assessment studies. Regul Toxicol Pharmacol. 2017;93(1): 92-104.
15. Forster M, Fiebelkorn S, Yurteri C, et al. Assessment of novel tobacco heating product THP1.0. Part 3: comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions. Regul Toxicol Pharmacol. 2017;93(1):14-33.
16. Forster M, McAughey J, Prasad K, et al. Assessment of tobacco heating product THP1.0. Part 4: characterisation of indoor air quality and odour. Regul Toxicol Pharmacol. 2017;93(1):34-51.
17. Thorne D, Breheny D, Proctor C, et al. Assessment of novel tobacco heating product THP1.0. Part 7: comparative in vitro toxicological evaluation. Regul Toxicol Pharmacol. 2017;93(1):71-83.
18. Taylor M, Thorne D, Carr T, et al. Assessment of novel tobacco heating product THP1.0. Part 6: A comparative in vitro study using contemporary screening approaches. Regul Toxicol Pharmacol. 2017;93(1): 62-70.
19. Jaunky T, Adamson J, Santopietro S, et al. Assessment of tobacco heating product THP1.0. Part 5: in vitro dosimetric and cytotoxic assessment. Regul Toxicol Pharmacol. 2017;93(1):52-61.
20. Gee J, Prasad K, Slayford S, et al. Assessment of tobacco heating product THP1.0. Part 8: study to determine puffing topography, mouth level exposure and consumption among Japanese users. Regul Toxicol Pharmacol. 2017;93(1):84-91.
21. Gale N, McEwan M, Eldridge AC, et al. A randomised, controlled, twocentre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional cigarette to a tobacco heating product. BMC Public Health. 2017;17(1):673.
22. Jaccard G, Tafin Djoko D, Moennikes O, Jeannet C, Kondylis A, Belushkin M. Comparative assessment of HPHC yields in the Tobacco Heating System THS2.2 and commercial cigarettes. Regul Toxicol Pharmacol. 2017;90(1):1-8.
23. Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012;14(1):75-78.
24. Murphy J, Gaca M, Lowe F, et al. Assessing modified risk tobacco and nicotine products: description of the scientific framework and assessment of a closed modular electronic cigarette. Regul Toxicol Pharmacol. 2017;90(1):342-357.
25. WHO Study Group. The Scientific Basis of Tobacco Product Regulation: Second Report of a WHO Study Group. World Health Organisation Technical Reports Series, 2008:1-277.
26. Haziza C, de La Bourdonnaye G, Skiada D, et al. Evaluation of the Tobacco Heating System 2.2. Part 8: 5-day randomized reduced exposure clinical study in Poland. Regul Toxicol Pharmacol. 2016;81(suppl 2):S139-S150.
27. Haziza C, de La Bourdonnaye G, Merlet S, et al. Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. Regul Toxicol Pharmacol. 2016;81(1):489-499.
28. Goniewicz ML, Havel CM, Peng MW, et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3421-3425.
29. Shiffman S, Scholl S. Increases in cigarette consumption and decreases in smoking intensity when non-daily smokers are provided with free cigarettes. Nicotine Tob Res. In press. doi:10.1093/ntr/ntx221
30. Park SL, Kotapati S, Wilkens LR, et al. 1, 3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2240-2249.